Derivative prodrugs of ethinyl estradiol

• US 7,795,241 B2
• Filed: 07/03/2006
• Issued: 09/14/2010
• Est. Priority Date: 07/12/2005
• Status: Active Grant

• Current Assignee: Allergan Therapeutics LLC (Abbvie Incorporated)
• Original Assignee: Warner Chilcott Company LLC (Abbvie Incorporated)
• Inventors: Keown, James, McIlroy, James William, King, John Alexander, Armstrong, William Paul, Gilligan, Claire
• Primary Examiner(s): Badio; Barbara P
• Application Number:
  US11/478,582
• Publication Number:
  US 20070015740A1
• Time in Patent Office: 1,534 Days
• Field of Search: 552/625, 514/182
• US Class Current: 514/182
• CPC Class Codes: A61P 5/30 Oestrogens
• CPC Class Codes: C07J 1/0096 Alkynyl derivatives
• CPC Class Codes: C07J 41/0072 the A ring of the steroid being aromatic
• CPC Class Codes: C07J 43/00 Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
• CPC Class Codes: C07J 43/003 not condensed
• CPC Class Codes: C07J 7/00 Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms C07J5/00 takes precedence

Abstract

The present invention is a prodrug derivative of ethinyl estradiol according to Formula I:

Claims

1. A compound having the following formula:

3. A method of providing contraception comprising the step of:

administering to a patient in need thereof, an effective amount of said compound of claim 1, for an effective period of time.

4. A method of providing hormone treatment therapy to a patient in need thereof, comprising the step of:

administering to said patient in need thereof, an effective amount of said compound of claim 1, for an effective period of time.

2. A pharmaceutical dosage unit comprising:

(a) a compound having the following formula;